Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€261.15

€261.15

-0.270%
-0.7
-0.270%
€315.23
 
25.07.25 / Tradegate WKN: 867900 / Symbol: AMGN / Name: Amgen / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Amgen Inc. Stock

The price for the Amgen Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.700 (-0.270%).
With 27 Buy predictions and 4 Sell predictions Amgen Inc. is one of the favorites of our community.
As a result the target price of 315 € shows a positive potential of 20.62% compared to the current price of 261.15 € for Amgen Inc..
Criterium "Balance Sheet Risk" is seen as the biggest plus for Amgen Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Amgen Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Amgen Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Amgen Inc. -0.270% 2.957% 8.586% -15.197% 4.231% 7.381% 22.634%
Regeneron Pharmaceuticals Inc. 0.500% 2.828% 7.480% -51.061% -29.051% -16.437% -8.276%
Exact Sciences 0.510% -4.883% -7.244% -7.379% -24.062% -7.431% -49.628%
Incyte Corp. 0.130% 2.398% 3.140% -5.501% -9.038% -24.185% -30.025%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-14

Die Geldeinnahmen von Amgen (US-Symbol AMGN) deuten auf eine starke Leistung hin, die sich in entscheidenden Finanzmetriken wie Umsatz, Betriebskapital und Rentabilität widerspiegelt. Die Bilanzen des Unternehmens über die Jahre zeigen eine beständige Vermögensbasis und anhaltende Rentabilität. Die Analyse der Cashflow-Berichte zeigt, dass das Unternehmen robuste Betriebscashflows generiert, was auf solide betriebliche Leistung und Liquiditätsmanagement hindeutet.

Gehen wir tiefer in die einzelnen Vorteile und Nachteile der Finanzen von Amgen ein.

Die umfangreichen Vermögenswerte von Amgen, wie in den Jahresbilanzen gezeigt, beinhalten sowohl kurzfristige Vermögenswerte, die eine starke Liquidität signalisieren, als auch längerfristige Vermögenswerte, die eine solide Investition in den Forschungs- und Entwicklungsbereich verdeutlichen.

Comments

Prediction Sell
Perf. (%) -0.23%
Target price 222.320
Change
Ends at 23.07.26

Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Bank of America Corporation from $252.00 to $261.00. They now have an "underperform" rating on the stock.
Ratings data for AMGN provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 9.63%
Target price 280.342
Change
Ends at 27.06.26

Amgen Inc. (NASDAQ: AMGN) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $328.00 price target on the stock.
Ratings data for AMGN provided by MarketBeat
Show more

Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for AMGN provided by MarketBeat
Show more

News

1 Top Dividend Growth Stock to Buy Right Now: https://g.foolcdn.com/editorial/images/823988/research-scientists-drugs-pharma-biotech.jpg
1 Top Dividend Growth Stock to Buy Right Now

Generating passive income is great for investors, and holding dividend-paying stocks is an excellent way to do that. However, not all corporations that pay dividends will be attractive to income

This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk: https://g.foolcdn.com/editorial/images/823129/someone-measuring-a-persons-waist.jpg
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk

There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk. But it could get much more crowded in the

Why Amgen Stock Popped by 4% Today: https://g.foolcdn.com/editorial/images/823600/person-in-a-lab-gazing-into-a-microscope.jpg
Why Amgen Stock Popped by 4% Today

Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4%